Urology>>>>>Prostate Cancer
Question 3#

Which of the following is TRUE regarding brachytherapy monotherapy for prostate cancer? 

A. Should be considered in the management of intermediate- and high-risk localised prostate cancer
B. HDR uses palladium103 as the radioactive source
C. Low dose rate (permanent seed implantation) (LDR) and high dose rate (HDR) temporary implantation represent the two types of brachytherapy
D. There is no limitation in relation to prostate size
E. A ‘PSA bounce’ is less common after brachytherapy than after external beam radiotherapy

Correct Answer is C


Answer C

According to NICE guidelines brachytherapy is considered an option in low- and intermediaterisk groups. Iridium192 is the radioisotope used in high dose brachytherapy in combination with external beam radiotherapy. Iodine125 and palladium103 are used in low dose brachytherapy. Prostate volume of 50–60 mL is considered the upper limit for BXT treatment due to pubic arch interference preventing insertion of the source in some of the anterior gland.

Further Reading:

Georgios Koukourakis et al. Brachytherapy for Prostate Cancer: A Systematic Review, Advances in Urology, Volume 2009, Article ID 327945, 11 pages.